AUTHORS
Shuaishuai Ge, MS, Kaixiu luo2, Lei Zhang, MD3, Meng Liu, MD4, Xin He, MD5, Haojie Dong, PhD6, Yini Wang7, Ruomei Wang8, Shengli Xue9, Jian Jin10, Ling Li, PhD11
AFFILIATIONS
1 City of Hope National Medical Center, Duarte, California, United States, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
10 Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Introduction: Acute myeloid leukemia (AML) remains largely refractory to immunotherapy owing to defective antigen presentation and profound immune evasion. Reanalysis of published genome-wide CRISPR immune screens (PMID: 36151395; 37557169) identified PRMT7, the only type III protein arginine methyltransferase, as a candidate regulator of immune response (ranked 46/11577) and antigen presentation (ranked 38/19114) in melanoma and AML cells, respectively. Analysis of patient datasets further demonstrated that PRMT7 is highly expressed in AML, particularly in MLL-rearranged leukemia, and that elevated PRMT7 expression is associated with inferior overall survival (TCGA). However, whether PRMT7 regulates leukemia immunogenicity and the underlying molecular mechanism remain unknown.
Methods: Hematopoietic-specific Prmt7 knockout mice (Prmt7fl/fl; Vav1-Cre) were generated to produce MLL-AF9 leukemia. Wild-type or Prmt7-deficient leukemia cells were transplanted into immunocompetent C57BL/6 or immunodeficient NSG recipients to distinguish immune-dependent from leukemia-intrinsic effects. Human AML lines including THP-1 and MOLM13 were subjected to genetic deletion, pharmacologic inhibition (SGC3027), or targeted degrader of PRMT7 (PROTAC). MHC-I (HLA/A/B/C) surface expression analysis, in vitro T cell cytotoxicity assay, and flow cytometric immune profiling in mouse leukemic bone marrow were assessed. RNA sequencing, Proteomics profiling of arginine methylation following PRMT7 PROTAC treatment and monomethyl arginine immunoprecipitation were used to define the underlying mechanism.
Results: Prmt7 deletion had no detectable effect on steady-state hematopoiesis with comparable hematopoietic stem and progenitor cell frequencies between knockout and control mice. In contrast, Prmt7 deficiency markedly delayed MLL-AF9 leukemia progression and prolonged survival in immunocompetent recipients (median survival, 40.5 days vs. not reached; P<0.001), but not NSG recipients (37 vs. 34 days; P=0.069), demonstrating that therapeutic efficacy depends on adaptive immunity rather than leukemia-intrinsic growth suppression. Bone marrow immune profiling revealed increased effector and IFN-γ-producing CD4? and CD8? T cells, reduced naïve T cells, and enhanced leukemia antigen (Survivin)-specific CD8? T-cel l responses. PRMT7 deficiency promoted about 2-fold upregulation of cell-surface MHC-I in both human (THP-1 and MOLML13) and MLL-AF9 AML cells and significantly enhanced CD8? T-cell cytotoxicity. Selective PRMT7 inhibition or targeted degradation phenocopied genetic deletion in MOLM13 and THP-1 cells. Re-expression of wild-type PRMT7 restored arginine monomethylation and suppressed MHC-I surface expression, whereas the catalytic-dead R44A mutant failed to rescue either phenotype, while cells expressing comparable levels of WT and R44A proteins. RNA sequencing revealed minimal changes in canonical MHC-I antigen-presentation genes, including HLA-A/B/C, B2M and NLRC5, indicating that PRMT7 regulates antigen presentation primarily through a post-transcriptional mechanism.
Proteomics profiling of arginine methylation identified PSMF1 R205 monomethylation as one of the most significantly reduced methylation events after PRMT7 degradation. Monomethylation immunoprecipitation confirmed markedly reduced methylation of the PSMF1-R205K mutant compared with wild-type PSMF1. Because PSMF1 negatively regulates proteasome activity, PRMT7-mediated PSMF1 methylation is proposed to enhance PSMF1-dependent suppression of proteasome-mediated antigen processing, thereby reducing the generation of peptides available for MHC-I loading. Consistently, PSMF1 deficiency phenocopied PRMT7 loss by increasing MHC-I surface expression and enhancing CD8? T-cell cytotoxicity, whereas re-expression of wild-type, but not methylation-deficient PSMF1-R205K, restored suppression of MHC-I presentation.
Conclusions: PRMT7 functions as an immune regulator in AML by suppressing MHC-I antigen presentation. Mechanistically, PRMT7 promotes leukemia immune evasion through methylation of PSMF1, thereby limiting proteasome-dependent antigen processing, reducing MHC-I peptide presentation, and impairing CD8? T-cell immunity. These findings establish a previously unrecognized connection between protein arginine methylation and leukemia immunogenicity and provide a strong rationale for combining PRMT7 inhibition with immune checkpoint blockade or other T-cell-based immunotherapies in AML.
DISCLOSURES
Shuaishuai Ge, MS: No relevant conflicts of interest to declare.